Influence of ticagrelor on levels of serum high sensitive C reactive protein and plasma homocysteine in patients with acute coronary syndrome／
10.3969/j.issn.1008-0074.2019.01.18
- VernacularTitle:替格瑞洛对急性冠脉综合征患者血清高敏 C 反应蛋白及血浆同型半胱氨酸水平的影响
- Author:
Dayu WANG
1
;
Shanjun ZHAO
;
Jiayong LIANG
;
Jianhao LI
;
Wenzhu ZHANG
;
Jun CHEN
Author Information
1. 广州市番禺区中心医院心血管内科
- Keywords:
Acute coronary syndrome;
C‐reactive protein;
Homocysteine;
Ticagrelor
- From:
Chinese Journal of cardiovascular Rehabilitation Medicine
2019;28(1):72-75
- CountryChina
- Language:Chinese
-
Abstract:
Objective :To explore influence of ticagrelor on levels of serum high sensitive C reactive protein (hsCRP) and plasma homocysteine (Hcy) in patients with acute coronary syndrome (ACS).Methods :A total of 135 ACS pa‐ tients hospitalized in our department from Jan 2016 to Feb 2017 were selected .Based on routine treatment ,Patients were randomly and equally divided into routine group ,clopidogrel group and ticagrelor group (based on routine treatment respectively received clopidogrel or ticagrelor ) for four weeks .Levels of serum hsCRP and plasma Hcy were measured and compared among all groups before and after treatment .Results :Compared with before treat‐ment ,after four‐week treatment , there were significant reductions in levels of serum hsCRP and plasma Hcy in three groups (P＜0. 05 or ＜0.01).Compared with routine group and clopidogrel group after four‐week treatment , there were significant reductions in levels of serum hsCRP [ (12.95 ± 1.99) mg／L , (8. 56 ± 1. 24) mg／L vs.(4. 47 ± 1. 92) mg／L] and plasma Hcy [ (13.48 ± 2.12) μmol／L , (9.55 ± 0. 94) μmol／L vs.(6. 61 ± 1. 15) μmol／L] in ticagrelor group ( P＜0.05 or ＜0.01).Conclusion :Ticagrelor can significantly reduce levels of serum hsCRP and plasma Hcy while effective antiplatelet therapy ,then significantly inhibit inflammatory response ,improve vascular endothelial function ,contribute to stabilizing atherosclerotic plaques ,improve prognosis in ACS patients .
